Zymeworks (ZYME) Cash & Equivalents (2021 - 2026)

Zymeworks has reported Cash & Equivalents for 6 years, with the latest figure at $244.3 million in Q1 2026.

• Quarterly Cash & Equivalents rose 220.56% year-over-year to $244.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $244.3 million (up 220.56% YoY) and the FY2025 annual result came in at $41.2 million, down 37.74% from the prior year.
• Cash & Equivalents advanced to $244.3 million in Q1 2026 per ZYME's latest filing, from $41.2 million in the prior quarter.
• Over five years, Cash & Equivalents peaked at $400.9 million in Q4 2022 and troughed at $41.2 million in Q4 2025.
• A 5-year average of $131.4 million and a median of $98.3 million in 2025 frame the typical range for Cash & Equivalents.
• The sharpest annual moves came in 2023 and 2026: Cash & Equivalents sank 60.7% in 2023, then jumped 220.56% in 2026.
• Over 5 years, Cash & Equivalents stood at $400.9 million in 2022, then tumbled by 60.7% to $157.6 million in 2023, then tumbled by 58.05% to $66.1 million in 2024, then plunged by 37.74% to $41.2 million in 2025, then surged by 493.54% to $244.3 million in 2026.
• According to Business Quant data, Cash & Equivalents over the past three periods registered $244.3 million, $41.2 million, and $64.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.